Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In Situ Bevacizumab for Complex Brain Arteriovenous Malformations
NCT07075757Phase 1Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2025
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab in brain arteriovenous malformation (AVM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Dose Limiting Toxicity at 30 days. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
brain arteriovenous malformation (AVM)
Beyond the preview
Go deeper on NCT07075757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075757.